Annual Meeting of European Competence Network on Mastocytosis

Slides:



Advertisements
Similar presentations
Introduction Parkinsons disease is not just a burden for the patients it also has a substantial social and economic impact. The European countries differ.
Advertisements

Erdheim-Chester Disease
European Guidelines for the HIV Treatment Esteban Martínez Infectious Diseases Unit Hospital Clínic University of Barcelona Barcelona SPAIN.
How to Manage High Risk Myeloma Dr Matthew Jenner Consultant Haematologist Southampton General Hospital UK Myeloma Forum Autumn Day 12 November 2014.
CLL- Chronic Lymphocytic Leukemia
IMMUNE THROMBOCYTOPENIA Cathy Payne MSN, ACNP-BC Hematology/Oncology Nurse Practitioner Ironwood Cancer and Research Centers.
Leukemia By Mary Chen and Genesis Pimentel
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Educational Presentation. Program Overview Provide information on The Leukemia & Lymphoma Society Describe blood cancers Explain Pennies for Patients.
Centre for Innovation, Technology Transfer and University Development Jagiellonian University Centre for Innovation, Technology Transfer and University.
Rare Diseases Working Group Luzern, 24 September 2010.
Rare Diseases Foundation Céline Hubert Pr Nicolas Lévy
Chronic lymphocytic leukemia (1)
Chronic Lymphocytic Leukemia (CLL) DEFINITION CLL is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid.
Dermatology Aspects of Cutaneous T-cell Lymphoma
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
SOS DESMOIDE ASSOCIATION Marie Podevin CTOS Meeting November 21 st, Boca Raton, Florida.
What Clinical Trials Can We Expect for RD in the Future? Groups of investigators are now working on several of the Rare Diseases to move to Trials. 1)Leber.
BioSciencs Foro November 8th, New York Joaquin Guinea Chairman of BIOMADRID (
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.
Hodgkin’s Lymphoma By: Tonya Weir and Paige Mathias Date: October 13, 2010.
European Society of Cardiology Cardiovascular diseases in women.
Very Bright Worship Service Facts to Break Sickle Silence ® September , 2010.
The Future of Cancer and Treatments Abby Bridge AP Biology Period 1.
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
Is Cancer Really that Dangerous? Cause of Death Lifetime odds of dying Car Crash1 in 242 Drowning1 in 1,028 Plane Crash1 in 4,608 Lightning1 in 71,501.
Leukemia.
EURORDIS Eurordis Position on Research Priorities for Rare Diseases.
OMICS international Contact us at: OMICS International through its Open Access Initiative is committed to make genuine and.
Cancer – A general term for more than 250 diseases characterized by abnormal and uncontrolled growth of cells.
ANAEMIA ŞİFA-TUĞÇE.
Blood Cancers in older adults Cancer and Older Adults 19 November 2015 Matthew Foster, MD Assistant Professor of Medicine Leukemia, Lymphoma and Myeloma.
Hematology and Hematologic Malignancies
Educational Presentation
Cancer: Uncontrolled Cell Division Biology 12. Some Stats from WHO: Cancer is a leading cause of death group worldwide and accounted for 7.4 million deaths.
HEMATOPATHOLOGY MODULE Prepared by Emmanuel R. de la Fuente, M.D.
By: Ashlynn Hill. Patrice Thompson  3 year who is battling leukemia.  The doctors suggest a bone marrow transplants for a long term survival.  Neither.
Breast Cancer »Breast cancer is a malignant tumor that starts in the cells of the breast. »The disease occurs almost entirely in women,but men can get.
Good Afternoon My name is Iris Bassi and I have great pleasure in welcoming you all to this inaugural European LAM Scientific and Patient Conference I.
PRACTICE TEACHING ON THALASSEMIA. INTRODUCTION O Inherited blood disorder O an abnormal form of hemoglobin due to a defect through a genetic mutation.
Mastocytosis Proliferation of mast cells accumulation in organs Heterogen. manifestations (spontan. regression x aggresive) Cutaneous Systemic.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
STEM CELL TREATMENT IN INDIA Why to chose stem cell treatment in India?
Presentation On gaucher’s disease
Acute Leukemia Kristine Krafts, M.D..
EULAR Study Group on Systemic Lupus Erythematosus (SLE) Dimitrios T
Case Report: Cutaneous Mastocytosis in Infant
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Ductal Carcinoma (Breast Cancer)
Cancer Cancer – A general term for more than 250 diseases characterized by abnormal and uncontrolled growth of cells.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD) V. Smith*1, A. Herrick2, A. Sulli3 and M. Cutolo3 1Ghent University Hospital, University.
Case Studies.
This talk will follow the topical structure suggested by the ABP:
Seasonal Allergic Rhinitis
EULAR Study Group on Systemic Lupus Erythematosus (SLE) Dimitrios T
Center of Medical Mycology
Tbilisi Oncodipensary - Tbilisi Cancer Center
Follow-Up of the Patient After PE
1st Annual Patient-Healthcare Provider Conference
Hairy cell Leukemia Case study.
Immunotherapy for cSCC
Physician Diagnosis and Prescription
Cancer: Uncontrolled Cell Division
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Quantock Medical Centre BOOK YOUR APPOINTMENT NOW!
Merging the Art and Science of Managing nOH in Clinical Practice
How to establish the diagnosis of LGL leukemia.
Presentation transcript:

Annual Meeting of European Competence Network on Mastocytosis 13-14 November 2009, Medical University of Gdańsk, Poland

Invitation Annual Meeting of European Competence Network on Mastocytosis 13-14 November 2009, Medical University of Gdańsk,Poland Invitation Mastocytosis is a group of rare diseases characterized by an abnormal growth of mast cells in skin, bone marrow, liver, spleen, lymph nodes. Signs and symptoms result mostly from mast cells mediators and mast cells organ infiltration. Therapy covers patient education, symptomatic treatment, immunotherapy and chemiotherapy. The European Competence Network on Mastocytosis, ECNM, is a „non-profit” cooperative initiative of a group of scientists and clinicians in Europe who are devoted to merge their efforts in an attempt to improve recognition, diagnosis, and therapy in patients with mastocytosis. The annual meeting in 2009 will take place in Gdansk. Leading scientists (allergologists, dermatologists, hematologists) from Europe, USA and other countries will discuss the latest findings in pathophysiology, diagnosis and therapy of the disease. Future research projects, clinical trials and scientific cooperation will be discussed. The meeting is also the place for the presentation of novel diagnostic and pharmacological products by the companies involved in the field. The meeting is opened for all scientists and physicians. On behalf of the Gdańsk Centre of European Competence Network on Mastocytosis we are honored to invite you for the event.

Annual Meeting of European Competence Network on Mastocytosis 13-14 November 2009, Medical University of Gdańsk, Poland Preliminary programme Friday Sessions 1. Opening 2. Epidemiology of mastocytosis, national and European registries of mastocytosis 3. Diagnosis, new mediators, mutations and gene polymorphisms 4. Mediator related symptoms prophylaxis and management 5. Insect venom immunotherapy in mastocytosis 6. Women and children with mastocytosis 7. Aggressive mastocytosis and chemiotherapy 8. Clinical trials in mastocytosis Lunch – congress center Dinner in the Old City of Gdansk Saturday 1. Mast cell - highlights from the basic science 2. From basic science to the disease new approaches in mastocytosis 3. Closing remarks and end of the meeting